How HIV treatment could result in effective prevention

Future Virology

Volumn 5, Issue 4, 2010, Pages 405-415

  Venkatesh, Kartik K ^a   Lurie, Mark N ^a   Mayer, Kenneth H ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

AIDS; antiretrovirals; highly active antiretroviral therapy; HIV; prevention; treatment

Indexed keywords

EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; VIRUS REPLICATION;

EID: 77954901303     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.38     Document Type: Review

References (101)

1. Braitstein P, Brinkhof MW, Dabis F et al.; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367(9513), 817-824 (2006).
2. Palella F, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860 (1998).
3. Bartlett J, Shao JF: Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis. 9(10), 637-649 (2009).
4. Harrington M, Carpenter CC: Hit HIV-1 hard, but only when necessary. Lancet 355(9221), 2147-2152 (2000).
5. Wilkin T, Gulick RM: When to start antiretroviral therapy? Clin. Infect. Dis. 47(12), 1580-1586 (2008).
6. Lane H, Neaton JD: When to start therapy for HIV infection: a swinging pendulum in search of data. Ann. Int. Med. 138(8), 680-681 (2003).
7. Granich R, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373(9657), 48-57 (2009).
8. Dodd P, Garnett GP, Hallett TB: Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24(5), 729-735 (2010).
9. Quinn T: HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 22(Suppl. 3), S7-S12 (2008).
10. WHO: Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. WHO Press, Geneva, Switzerland (2009)
11. Montaner J, Hogg R, Wood E et al.: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368(9534), 531-536 (2006).
12. Stephenson J: Scientists explore use of anti-HIV drugs as a means to slow HIV transmission. J. Am. Med. Assoc. 303(18), 1798-1799 (2010).
13. Cu-Uvin S, Caliendo AM, Reinert S et al.: Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 14(4), 415-421 (2000).
14. Vernazza P, Gilliam BL, Flepp M et al.: Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 11(10), 1249-1254 (1997). (Pubitemid 27298091)
15. Jackson J, Musoke P, Fleming T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362(9387), 859-868 (2003).
16. Karon J, Fleming PL, Steketee RW, De Cock KM: HIV in the United States at the turn of the century: an epidemic in transition. Am. J. Public Health 91(7), 1060-1068 (2001).
17. Quinn TC MJ, Wawer N, Sewankambo D et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921-929 (2000).
18. Tovanabutra S, Robison V, Wongtrakul J et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J. Acquir. Immune Defic. Syndr. 29(3), 275-283 (2002).
19. Musicco M, Lazzarin A, Nicolosi A et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch. Intern. Med. 154(17), 1971-1976 (1994).
20. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr. 40(1), 96-101 (2005).
21. Donnell D, Kiarie J, Thomas K et al.: ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16-19 February 2010.
22. Das-Douglas M, Chu P, Santos GM et al.: Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16-19 February 2010.
23. Montaner J, Wood E, Kerr T et al.: Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in british columbia, canada. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16-19 February 2010.
24. Cohen M, Gay C, Kashuba AD, Blower S, Paxton L: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Int. Med. 146(8), 591-601 (2007).
25. Parker R: Civil society, political mobilization, and the impact of HIV scale-up on health systems in Brazil. J. Acquir. Immune Defic. Syndr. 52(Suppl. 1), S49-S51 (2009).
26. Ainsworth M, Beyrer C, Soucat A: AIDS and public policy: the lessons and challenges of "success" in Thailand. Health Policy 64(1), 13-37 (2001).
27. Fang C, Hsu HM, Twu SJ et al.; Division of AIDS and STD, Center for Disease Control, Department of Health, Executive Yuan: decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J. Infect. Dis. 190(5), 879-885 (2004).
28. Achmat Z, Simcock J: Combining prevention, treatment and care: lessons from South Africa. AIDS 21(Suppl. 4), S11-S20 (2007).
29. Chopra M, Lawn JE, Sanders D et al.\ Lancet South Africa team: achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet 374(9694), 1023-1031 (2009).
30. Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D: The health and health system of South Africa: historical roots of current public health challenges. Lancet 374(9692), 817-834 (2009).
31. Bunnell R, Opio A, Musinguzi J et al.: HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS 22(5), 617-624 (2008).
32. Harries A, Schouten EJ, Libamba E: Scaling up antiretroviral treatment in resource-poor settings. Lancet 367(9525), 1870-1872 (2006).
33. El-Sadr W, Mayer KH, Hodder SL: AIDS in America - forgotten but not gone. N. Engl. J. Med. 362(11), 967-970 (2010).
34. Pilcher C, Tien HC, Eron JJ Jr et al.; Quest Study; Duke-UNC-Emory Acute HIV Consortium: Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189(10), 1785-1792 (2004).
35. Hirsch M: Initiating therapy: when to start, what to use. J. Infect. Dis. 197(Suppl. 3), S252-S260 (2008).
36. Brenner B, Roger M, Routy JP etal.\ Quebec Primary HIV Infection Study Group: High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195(7), 951-959 (2007).
37. Wawer M, Gray RH, Sewankambo NK et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191(9), 1403-1409 (2005).
38. Streeck H, Jessen H, Alter G et al. : Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J. Infect. Dis. 194(6), 734-739 (2004).
39. Hecht F, Wang L, Collier A et al.; AIEDRP Network: A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194(6), 725-733 (2006).
40. Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J. Acquir. Immune Defic. Syndr. 41(5), 632-641 (2006).
41. Garnett G, Gazzard B: Risk of HIV transmission in discordant couples. Lancet 372(9635), 270-271 (2008).
42. Jahn A, Floyd S, Crampin AC et al.: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371(9624), 1603-1611 (2008).
43. Walensky R, Wolf LL, Wood R et ah CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators: When to start antiretroviral therapy in resource-limited settings. Ann. Int. Med. 151(3), 157-166 (2009).
44. Velasco-Hernandez J, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect. Dis. 2(8), 487-493 (2002).
45. Lima VD, Johnston K, Hogg RS et al.: Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J. Infect. Dis. 198(1), 59-67 (2008).
46. Kumarasamy N, Venkatesh KK, Cecelia AJ t al.: Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDs 22(4), 337-344 (2008).
47. Bender M, Kumarasamy N, Mayer KH et al.: Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin. Infect. Dis. 50(3), 416-425 (2010).
48. Hammer S, Eron JJ Jr, Reiss P et al.\ International AIDS Society-USA: antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 300(5), 555-570 (2008).
49. May M, Sterne JA, Sabin C et al.; Antiretroviral Therapy (ART) Cohort Collaboration: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21(9), 1185-1197 (2007).
50. Lichtenstein K, Armon C, Buchacz K et al.\ HIV Outpatient Study (HOPS) Investigators: Initiation of antiretroviral therapy at CD4 cell counts >350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J. Acquir. Immune Defic. Syndr. 47(1), 27-35 (2008).
51. Kitahata M, Gange SJ, Abraham AG et al.; NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360(18), 1815-1826 (2009).
52. Moore R, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 44(3), 441-446 (2007).
53. Mocroft A, Phillips AN, Gatell J et al.; EuroSIDA Study Group: Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370(9585), 407-413 (2007).
54. Gras L, Kesselring AM, Griffin JT et al.; ATHENA, Netherlands National Observational Cohort Study: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J. Acquir. Immune Defic. Syndr. 45(2), 183-192 (2007).
55. Gilks C, Crowley S, Ekpini R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 568(9534), 505-510 (2006).
56. Libamba E, Makombe S, Harries AD et al.: Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. Int. J. Tuberc. Lung Dis. 9(10), 1062-1071 (2005).
57. Lowrance D, Makombe S, Harries AD et al.: A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J. Acquir. Immune Defic. Syndr. 49(3), 287-293 (2008).
58. Van Damme W, Kober K, Laga M: The real challenges for scaling up ART in sub-Saharan Africa. AIDS 20(5), 653-656 (2006).
59. Bates I, Maitland K: Are laboratory services coming of age in sub-Saharan Africa? Clin. Infect. Dis. 42(3), 383-384 (2006).
60. Harries A, Makombe SD, Schouten EJ, Ben-Smith A, Jahn A: Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of 'universal access'. Trans. R. Soc. Trop. Med. Hyg. 102, 310-311 (2008).
61. Reynolds S, Bartlett JG, Quinn TC, Beyrer C, Bollinger RC: Antiretroviral therapy where resources are limited. N. Engl. J. Med. 348(18), 1806-1809 (2003).
62. Harries A, Schouten EJ, Makombe SD et al.: Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull. World Health Organ. 85(2), 152-155 (2007).
63. Cohen J: HIV/AIDS. The great funding surge. Science 321(5888), 512-519 (2008).
64. Tassie J, Szumilin E, Calmy A, Goemaere E; Medecins Sans Frontieres: Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 17(13), 1995-1997 (2003).
65. Anema A, Wood E, Montaner JS: The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ 179(1), 13-14 (2008).
66. McNeil D: At front lines, AIDS war is falling apart. The New York Times 10 May 2010.
67. McCoy D, Chopra M, Loewenson R et al.: Expanding access to antiretroviral therapy in sub-Saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am. J. Public Health 95(1), 18-22 (2005).
68. Losina E, Yazdanpanah Y, Deuffic-Burban S et al.: The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antiviral Ther. 12(4), 543-551 (2005).
69. Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD: Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin. Infect. Dis. 34(10), 1391-1395 (2002).
70. Goldie S, Yazdanpanah Y, Losina E et al.: Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N. Engl. J. Med. 355(11), 1141-1153 (2006).
71. Freedberg K, Kumarasamy N, Losina E et al.: Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21(4), S117-S128 (2007).
72. Freedberg K, Losina E, Weinstein MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344(11), 824-831 (2001). (Pubitemid 32222162)
73. Granich R, Kahn J, Bennett R et al.; the ART IMPACT Study Group: Economic analysis of ART for prevention of HIV transmission in a South African generalized HIV epidemic setting. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16-19 February 2010.
74. Ventelou B, Moatti JP, Videau Y, Kazatchkine M: 'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS 22(1), 107-113 (2008).
75. Ivers L, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programs in resource- poor settings: a meta-analysis of the published literature. Clin. Infect. Dis. 41, 217-224 (2005).
76. Mukadi Y, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 15(2), 143-152 (2001).
77. Badri M, Wilson D, Wood R: Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359(9323), 2059-2064 (2002).
78. Fisher J, Smith L: Secondary prevention of HIV infection: the current state of prevention for positives. Curr. Opin. HIV AIDS4(4), 279-287 (2009).
79. Hogben M, Liddon N: Disinhibition and risk compensation: scope, definitions, and perspective. Sex. Transm. Dis. 35(12), 1009-1010 (2008).
80. Katz M, Schwarcz SK, Kellogg TA et al.: Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am. J. Public Health 92(3), 388-394 (2002).
81. Bunnell R, Ekwaru JP, Solberg P et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 20(1), 85-92 (2006).
82. Crepaz N, Hart TA, Marks G: Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. J. Am. Med. Assoc. 292(2), 224-236 (2004).
83. Farmer P, Leandre F, Mukherjee JS et al.: Community-based approaches to HIV treatment in resource-poor settings. Lancet 358(9279), 404-409 (2001).
84. Mills EJ, Nachega JB, Buchan I et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296(6), 679-690 (2006).
85. Oyugi J, Byakika-Tusiime J, Ragland K et al.: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21(8), 965-971 (2007).
86. Bangsberg DR: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin. Infect. Dis. 43(7), 939-941 (2006).
87. Paterson D, Swindells S, Mohr J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Int. Med. 133(1), 21-30 (2000).
88. Leigh Brown A, Frost SD, Mathews WC et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral- treated population. J. Infect. Dis. 187(4), 683-686 (2003). (Pubitemid 36250034)
89. Yerly S, Jost S, Telenti A et al.: Infrequent transmission of HIV-1 drug-resistant variants. Antivir. Ther. 9(3), 375-384 (2004).
90. Margot N, Lu B, Cheng A, Miller MD; Study 903 Team: Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 7(7), 442-450 (2006).
91. Daar E, Richman DD: Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res. Hum. Retroviruses 21(5), 343-357 (2005).
92. Bennett D, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Ther. 13(Suppl. 2), 1-13 (2008).
93. Cardo D, Culver DH, Ciesielski CA et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N. Engl. J. Med. 337(21), 1485-1490 (1997).
94. Baggaley R, Ferguson NM, Garnett GP: The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg. Themes Epidemiol. 10(2), 9 (2005).
95. De Cock K, Gilks CF, Lo YR, Guerma T: Can antiretroviral therapy eliminate HIV transmission? Lancet 373(9657), 7-9 (2009).
96. Walensky R, Paltiel AD, Losina E et al.: The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194(1), 11-19 (2006).
97. Vernazza P, Hirschel B, Bernasconi E, Flepp M: Les personnes seropositives ne souff rant d'aucune autre MST et suivant un traitment antiretroviral effi cie ne transmettent pas le VIH par voie sexuelle. Bull. Med. Suisses 89, 165-169 (2008).
98. Boyd M, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS 21(Suppl. 4), S55-S63 (2007).
99. Pujades-Rodrfguez M, O'Brien D, Humblet P, Calmy A: Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 22(11), 1305-1312 (2008).
100. Venkatesh K, Kumarasamy N, Mayer KH: Indian manufacture of new generic antiretrovirals: implications for global access to anti-HIV drugs. HIVTher. 4(1), 1-4 (2010).
101. 2008 update on the global AIDS epidemic. http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008- Global-report.asp.